Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

KN-93 Phosphate

Copy Product Info
😃Good
Catalog No. T2606Cas No. 1913269-12-1

KN-93 (Phosphate) can competitively block the binding of calmodulin to the corresponding kinase. It is a calcium/calmodulin-dependent kinase II (CaMKII) inhibitor with a Ki of 370 nM. It can also inhibit the proliferation of human hepatic stellate cells.

KN-93 Phosphate

KN-93 Phosphate

Copy Product Info
😃Good
Purity: 99.93%
Catalog No. T2606Cas No. 1913269-12-1
KN-93 (Phosphate) can competitively block the binding of calmodulin to the corresponding kinase. It is a calcium/calmodulin-dependent kinase II (CaMKII) inhibitor with a Ki of 370 nM. It can also inhibit the proliferation of human hepatic stellate cells.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$44In StockIn Stock
5 mg$98In StockIn Stock
10 mg$147In StockIn Stock
25 mg$297In StockIn Stock
50 mg$553In StockIn Stock
100 mg$798In StockIn Stock
500 mg$1,590-In Stock
1 mL x 10 mM (in DMSO)$142In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.93%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
KN-93 (Phosphate) can competitively block the binding of calmodulin to the corresponding kinase. It is a calcium/calmodulin-dependent kinase II (CaMKII) inhibitor with a Ki of 370 nM. It can also inhibit the proliferation of human hepatic stellate cells.
Targets&IC50
CaMK II:0.37 μM(Ki)
In vitro
METHODS: PCI2h cells were treated with KN-93 (0, 1, 2, 5, 10 μM) and dopamine content was measured.
RESULTS KN-93 reduced dopamine (DA) content in a dose-dependent manner. [3]
METHODS: Human hepatic stellate cells (LX-2) were treated with KN-93 (0-50 μM), cell proliferation was detected by CCK-8 method, and the expression of two cell cycle regulators, p53 and p21, was detected by SDS-PAGE and Western blotting.
RESULTS KN-93 (5-50 μM) reduced the proliferation of human hepatic stellate cells in a dose-dependent manner, from 81.76% to 27.15% after 24 hours of treatment; 10 μM KN-93 incubation induced a time-dependent decrease in cell growth, from 78.27% at 8 h to 11.48% at 48 h; cell cycle regulator expression analysis showed that KN-93 reduced the expression of p53 and p21. [5]
In vivo
METHODS: 6-hydroxydopamine (OHDA) injection induced PD model in rats, and different doses of KN-93 (1 μg, 2 μg, or 5 μg) were administered into the striatum of successfully lesioned rats before L-DOPA treatment. Abnormal involuntary movement (AIM) scores and apomorphine-induced rotations were measured in PD rats. Phosphorylation level of GluR1 at Serine-845 (pGluR1S845) level was determined by western blot. Arc and Penk levels were measured by real-time polymerase chain reaction (PCR).
RESULTS Both 2 μg and 5 μg KN-93 treatment reduced the AIMs scores of L-dopa-induced PD rats without affecting the anti-parkinsonian effect of L-dopa; consistent with behavioral analysis, KN-93 (2 μg) treatment reduced the level of pGluR1S845 in PD rats and also reduced the expression of Gad1 and Nur77 in PD rats. [1]
METHODS: KN-93 (0.24 mg/kg, intraperitoneal injection, three times a week) treated MRL/lpr Foxp3-GFP mice, harvested lymphoid organs, and determined the number of Foxp3 cells; from MRL/lpr Foxp3-GFP mice Naïve CD4 cells were isolated from the spleen and cultured in vitro under Treg polarizing conditions to determine whether they could prevent disease progression.
RESULTS Treg cells in PBS-treated mice gradually decreased, while Treg cells in KN-93-treated mice remained stable and significantly increased; more GFP-positive cells were found in the spleen and peripheral lymph nodes of KN-93-treated mice. ; The percentage of Treg cells was higher in the presence of KN-93 in a dose-dependent manner. [2]
Chemical Properties
Molecular Weight599.03
FormulaC26H32ClN2O8PS
Cas No.1913269-12-1
SmilesOP(O)(O)=O.COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1
Relative Density.no data available
Storage & Solubility Information
StorageIn solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 135 mg/mL (225.36 mM), Sonication is recommended.
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 100 mg/mL (166.94 mM), Sonication is recommended.
In Vivo Formulation
Saline: < 1 mg/mL (insoluble or slightly soluble)
PBS: < 1 mg/mL (insoluble or slightly soluble)
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
H2O/DMSO
1mg5mg10mg50mg
1 mM1.6694 mL8.3468 mL16.6937 mL83.4683 mL
5 mM0.3339 mL1.6694 mL3.3387 mL16.6937 mL
10 mM0.1669 mL0.8347 mL1.6694 mL8.3468 mL
20 mM0.0835 mL0.4173 mL0.8347 mL4.1734 mL
50 mM0.0334 mL0.1669 mL0.3339 mL1.6694 mL
100 mM0.0167 mL0.0835 mL0.1669 mL0.8347 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy KN-93 Phosphate | purchase KN-93 Phosphate | KN-93 Phosphate cost | order KN-93 Phosphate | KN-93 Phosphate chemical structure | KN-93 Phosphate in vivo | KN-93 Phosphate in vitro | KN-93 Phosphate formula | KN-93 Phosphate molecular weight